Low-Dose Rivaroxaban to Prevent Left Ventricular Thrombosis After Anterior Myocardial Infarction

Does adding low-dose rivaroxaban to dual antiplatelet therapy (DAPT) reduce left ventricular (LV) thrombus formation in patients with anterior acute myocardial infarction?In this randomized clinical trial of 560 patients with anterior ST-segment elevation myocardial infarction (STEMI), adding low-dose rivaroxaban to DAPT did not significantly reduce LV thrombus formation at 1 month but did increase minor bleeding.In this study, in patients with anterior STEMI, the addition of low-dose rivaroxaban to DAPT did not demonstrate a statistically significant reduction in LV thrombus formation at 1 month but increased minor bleeding; given the limited power of the study, these findings should be interpreted with caution.

Corresponding Author: Etienne Puymirat, MD, PhD, Department of Cardiology, Hôpital Européen Georges-Pompidou, 20 Rue Leblanc, 75015 Paris, France (etienne.puymirat@aphp.fr).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.